dcsimg Aranesp® (darbepoetin alfa) – Duration of Action
› Email› Print

Aranesp® provides extended dosing intervals of QW and Q2W
for patients on dialysis, and Q4W for patients not on dialysis

Aranesp® has a unique molecular structure

Aranesp® provides a longer duration of action2,3*

1. Sustained efficacy at extended dosing intervals for patients on dialysis. 2. Sustained efficacy at extended dosing intervals for patients not on dialysis

Important Safety Information

  • Cases of PRCA and of severe anemia, with or without other cytopenias that arise following the development of neutralizing antibodies to erythropoietin have been reported in patients treated with Aranesp®.
    • This has been reported predominantly in patients with CKD receiving ESAs by subcutaneous administration.
    • PRCA has also been reported in patients receiving ESAs for anemia related to hepatitis C treatment (an indication for which Aranesp® is not approved).
    • If severe anemia and low reticulocyte count develop during treatment with Aranesp®, withhold Aranesp® and evaluate patients for neutralizing antibodies to erythropoietin.
    • Permanently discontinue Aranesp® in patients who develop PRCA following treatment with Aranesp® or other erythropoietin protein drugs. Do not switch patients to other ESAs.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease; QW = once weekly; Q2W = once every 2 weeks; Q4W = once every 4 weeks; TIW = three times weekly.
References: 1. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21:414-421. 2. Aranesp® (darbepoetin alfa) prescribing information, Amgen. 3. Vanrenterghem Y, Bárány P, Mann JFE, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002;62:2167-2175.

Biotechnology by Amgen®